Lantheus Holdings Inc. (LNTH) Sees Strong Trading Volume
Shares of Lantheus Holdings Inc. (NASDAQ:LNTH) saw strong trading volume on Monday . 788,984 shares were traded during trading, an increase of 157% from the previous session’s volume of 306,508 shares.The stock last traded at $7.70 and had previously closed at $6.45.
A number of research analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Lantheus Holdings from a “buy” rating to a “hold” rating in a research report on Thursday, May 12th. Jefferies Group restated a “buy” rating on shares of Lantheus Holdings in a research report on Wednesday, May 4th. Finally, Credit Suisse Group AG set a $4.00 price objective on shares of Lantheus Holdings and gave the company a “hold” rating in a research report on Friday, August 5th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $5.80.
The firm has a market cap of $211.80 million and a price-to-earnings ratio of 7.87. The firm has a 50-day moving average of $4.75 and a 200-day moving average of $2.81.
Lantheus Holdings (NASDAQ:LNTH) last issued its earnings results on Thursday, August 4th. The company reported $0.24 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.18. The firm earned $78 million during the quarter, compared to analyst estimates of $72.66 million. Analysts predict that Lantheus Holdings Inc. will post $0.53 EPS for the current fiscal year.
Lantheus Holdings, Inc develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.